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Abstract UDP-galactose:ceramide galactosyltransferase
(CGT) catalyzes the final step in the synthesis of galactosyl-
ceramide (GalCer). It has previously been shown that CGT-





-sulfate (galactosylsulfatide, SM4s) but
form myelin containing glucosylceramide (GlcCer) and sphin-
gomyelin with 2-hydroxy fatty acids. Because relatively high
concentrations of GalCer and SM4s are present also in
mammalian kidney, we analyzed the composition of lipids


























Cer), and SM4s. Yet, they did not
show any major morphological or functional defects in the
kidney. A slight increase in GlcCer containing 4-hydroxy-
sphinganine was evident among neutral glycolipids. Intrigu-





























 mice, indicating upregulation of biosynthe-
sis of SB1a from GlcCer via SM3. Given that SM4s is a ma-
jor polar glycolipid constituting renal tubular membrane,
the increase in SM3 and SB1a in the mice deficient in CGT
and thus SM4s appears to be a compensatory process,
which could partly restore kidney function in the knockout
mice.
 
—Tadano-Aritomi, K., T. Hikita, H. Fujimoto, K. Suzuki,
K. Motegi, and I. Ishizuka.
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Galactosylceramide (GalCer) and its sulfated derivative,
GalCer sulfate (galactosylsulfatide, SM4s), are present most
abundantly in the brain of vertebrates, comprising almost
one-third of the lipid mass of myelin. [Note: Abbrevia-
tions for sulfoglycolipids follow the modifications of the
Svennerholm system (1), and the designation of the other
glycolipids follows the IUPAC-IUB recommendations
(2).] Knockout mice with a disrupted UDP-galactose:cera-
mide galactosyltransferase (CGT) gene have been gener-
ated by gene targeting (3–5). The homozygous mutant
mice, which are incapable of synthesizing either GalCer or
SM4s, form myelin containing elevated amount of gluco-
sylceramide (GlcCer) and sphingomyelin with 2-hydroxy
fatty acids. Nevertheless, these mice display a variety of
deficits in myelin structure, function, and stability, indicat-
ing that both GalCer and SM4s are indispensable compo-
nents of myelin (4, 6). GalCer and/or SM4s are present in
glandular epithelial tissues including kidney and the islet
of Langerhans (7), where sulfoglycolipids are believed to
be essential components of surface membrane as the am-
phiphilic donor of negative charges (8). Although the
function of GalCer and SM4s in these tissues is not clear as
yet, CGT-deficient mice should provide useful keys to de-
lineate the roles of sulfolipids. Here, we analyze the lipids




















 and wild-type mice and investigate the effect of
elimination of GalCer and SM4s on renal function.
 
Abbreviations: Cer, ceramide; DMB, 1,2-diamino-4,5-(methylene-

















































































































lesterol 3-sulfate; HFA, 2-hydroxy fatty acid; d18:1, 4-sphingenine; t18:0,
4-hydroxysphinganine; PAS, periodic acid Schiff; TLC, thin-layer




This work was presented in part at the XVth International Symposium
on Glycoconjugates and has been published in abstract form (Tadano-
Aritomi, K., T. Hikita, H. Fujimoto, K. Suzuki, and I. Ishizuka. 1999. Gly-
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 gene were generated as described previously




 gene was inactivated by inser-
tion of the neomycin resistance gene into exon 2, which encodes
the N-terminal half of the CGT enzyme. The mice heterozygous




 gene were originally supplied by B. Popko
(University of North Carolina School of Medicine, Chapel Hill,
NC) and maintained in the Mitsubishi Kasei Institute of Life Sci-
ences (Tokyo, Japan) by backcrossing to C57BL/6N. The mice
used for experiments were generated by interbreeding of het-
erozygotes. For genotyping of mice, DNA isolated from tail bi-




HI, and hybridized with pCR550





 exon 2 as a probe for Southern blot analyses. A










 mice contained 8- and 9-kb bands. Heterozygotes had all
three bands.
Kidney function tests were done in the laboratory of one of
the authors (K.M.) by adapting routine clinical analysis proce-
































 5) mice. Detailed




Kidneys were dissected and fixed in Bouin’s solution over-





m sections were stained for the periodic acid –Schiff
(PAS) reaction followed by hematoxylin staining.
 
Lipid extraction and analysis
 
Pooled kidneys (2–8 g) from 7- to 12-week-old mice of each
genotype and sex were extracted with 19 volumes of chloroform –
methanol 2:1 (v/v) and with 10 volumes of chloroform –
methanol–water 60:120:9 (v/v/v) successively (9). The pooled
extracts (the total lipid extract) were chromatographed on a
DEAE-Sephadex A-25 column. After washing out neutral lipids,
acidic lipids were eluted sequentially by a concave gradient of am-





 methanolic NaOH to destroy glycerophospholipids.
Acidic lipids were further separated on silica gel 60 high-per-
formance thin-layer chromatography (TLC) plates (E. Merck,
Darmstadt, Germany) in chloroform –methanol–water 60:40:9













chloroform–methanol–acetone–acetic acid–water 7:2:4:2:1 (v/
v/v/v/v). The total lipid extract and the neutral glycolipid frac-
tion were analyzed by two-dimensional TLC, using the solvent





 (first direction) and chloroform–
methanol–acetone–acetic acid–water 7:2:4:2:1 (v/v/v/v/v) (sec-









B 50:20:1 (v/v/v) for the








OH–methyl acetate–water 5:2:1:3 (v/v/v/v) for the separation













 24:0/d18:1) from porcine pancreas (13) was
kindly provided by K. Nakamura (Kitasato University School of
Medicine, Kitasato, Japan). The bands were visualized with orci-
nol (hexose-containing lipids) (14), Azure A (sulfolipids) (11), re-
sorcinol (gangliosides) (15), or cupric acetate –phosphoric acid
(phospholipids and other lipids) (16). Lipids on the plates were
determined by densitometry (CS-9000; Shimadzu, Kyoto, Japan)
by comparison with known amounts of authentic standards.
Identification of lipids was performed by negative-ion liquid
secondary ion mass spectrometry (LSIMS) on a Concept IH
mass spectrometer (Shimadzu/Kratos, Kyoto, Japan) (17). Each
lipid developed by one- or two-dimensional TLC was transferred
to a polyvinylidene difluoride membrane (Clear Blot Mem-
brane-P; ATTO, Tokyo, Japan) by TLC blotting, and the band on
the membrane was excised and placed on a mass spectrometer
probe tip with triethanolamine as the matrix (18).
The concentrations of lipid-bound sulfate, sialic acids, and
phosphorus were determined with an aliquot of the neutral lipid
fraction or the pooled fraction from DEAE-Sephadex. For sul-












was determined by ion chromatography (Tadano-Aritomi et al.,
unpublished observations) (19). Ganglioside sialic acids were
determined as their 1,2-diamino-4,5-(methylenedioxy)benzene
(DMB) derivatives by high-performance liquid chromatography
(HPLC) (20). Phospholipid phosphorus was measured by the




Characteristics of CGT-deficient mice
 
The homozygous mutant mice (7 to 12 weeks of age)
exhibited a characteristic phenotype, with a body weight





















 mice was approximately two-
thirds that of wild-type and heterozygous littermates, sim-











than the smaller size, no evidence of abnormality was rec-










 mice (data not shown).










 mice, several pa-


























cosaminidase (NAG) excretion were measured in serum




 SD) are as follows:














































0.1 (Cgt1/2), 1.0 6 0.2 (wild type); Na1 (mEq/L), 152 6
3 (Cgt2/2), 149 6 3 (Cgt1/2), 149 6 4 (wild type); K1
(mEq/L), 5.3 6 1.7 (Cgt2/2), 5.1 6 1.3 (Cgt1/2), 4.9 6
0.3 (wild type); Cl2 (mEq/L), 118 6 1 (Cgt2/2), 117 6 2
(Cgt1/2), 116 6 2 (wild type); urinary osmolality (mOsm/
kg), 2,137 6 28 (Cgt2/2), 1,600 6 438 (Cgt1/2), 1,922 6
237 (wild type); NAG (U/L), 64 6 12 (Cgt2/2), 47 6 10
(Cgt1/2), 61 6 12 (wild type). All of these data were
within the normal range and no significant differences
were observed among Cgt2/2, Cgt1/2, and wild-type mice.
GalCer and Ga2Cer are absent from neutral lipids
As shown in Fig. 1, neutral glycolipids consisted of mono-
hexosylceramide (HexCer), dihexosylceramide (Hex2Cer),
globotriaosylceramide (Gb3Cer), and globotetraosylcera-
mide (Gb4Cer) as well as more polar glycolipids. Consis-
tent with previous studies (22, 23), the profile of the male
differed conspicuously from that of the female. The bands
corresponding to Hex2Cer and Gb3Cer were significantly
reduced not only in the kidney of the female mice of
three genotypes but also in the Cgt2/2 male mice. To dif-
ferentiate LacCer and Ga2Cer, the neutral lipid fractions
were analyzed by two-dimensional TLC with 2-propanol–
15 m NH4OH–methyl acetate–water (12) as the second
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developing solvent (data not shown). The three bands,
which migrated faster than LacCer but similar to Ga2Cer
(24), were detected only in the kidney of the male wild-
type and Cgt1/2 mice. Together with their LSIMS spectra,
these bands were identified as Ga2Cer with major fatty
acid/sphingoid of 24:0/d18:1, 16:0/d18:1, and 16h:0/
d18:1, respectively (Table 1). As expected, Ga2Cer was
also absent in the kidney of Cgt2/2 mice. LacCer could be
detected neither in the kidney of Cgt2/2 mice nor in those
of Cgt1/2 and wild-type littermates (22) with the sensitivity
of the analytical procedure used in this study.
HexCer represented a minor component among gly-
colipids in the kidney of six mice groups (three genotypes
in both sexes) (Fig. 1). By two-dimensional TLC with the
(CH3O)3B-containing solvent followed by negative-ion
LSIMS, four faint bands were identified as GlcCer(24h:0/
d18:1), GlcCer(24:0/t18:0), GlcCer(24h:0/t18:0), and
GalCer(24h:0/d18:1) (Table 1). In the kidney of Cgt2/2
mice, the band corresponding to GalCer was absent. In-
stead, increases in GlcCer bands containing 4-hydroxysphin-
ganine (t18:0) were characteristic, although they repre-
sented only minor components among neutral glycolipids
in the kidney of Cgt2/2 mice.
Lack of SM4s produces a conspicuous
increase in more polar sulfoglycolipids
The bands of individual sulfolipid was identified by neg-
ative-ion LSIMS (Table 1). The major sulfolipid, SM4s,
comprises almost 75% (Table 2) of the sulfolipids in the
kidney of wild-type mice with three minor sulfolipids, that
is, LacCer II3-sulfate (SM3), Gg4Cer II3,IV3-bis-sulfate
(SB1a) (25), and cholesterol 3-sulfate (HSO3-Chol) (8).
As expected, TLC analysis demonstrated a lack of SM4s in
the kidney of Cgt2/2 mice (Fig. 1). Instead, a substantial
increase in SB1a with a small increase of SM3, respectively,
was the remarkable feature of the kidney of Cgt2/2 mice
as compared with those of wild-type and Cgt1/2 litter-
mates (Fig. 2). In the kidney of Cgt2/2 mice, the amounts
Fig. 1. (A and B) Two-dimensional TLC of a total lipid extract from the kidney of wild-type and Cgt2/2 mice of both sexes. An aliquot of
the total lipid extract corresponding to 2 mg of kidney was separated on a TLC plate with chloroform –methanol–water 60:35:8 (v/v/v) con-
taining 0.2% CaCl2 (first direction) and chloroform–methanol–acetone–acetic acid–water 7:2:4:2:1 (v/v/v/v) (second direction). Gly-
colipid bands were visualized with the orcinol reagent. Asterisks (*) indicate unidentified constituents that moved close to SM4s but ap-
peared brownish with orcinol reagent. M, Male; F, female.
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of SM3 and SB1a, determined by ion chromatography,
were approximately 2- and 3-fold, respectively, the level of
wild-type or Cgt1/2 mice, while the level of HSO3-Chol re-
mained unchanged (Table 2). In contrast to the homozy-
gote sciatic nerve (26), no compensatory appearance of
glucosylsulfatide (GlcCer I3-sulfate) (11) was noted in the
kidney of Cgt2/2 mice.
Gangliosides and phospholipids are unchanged
TLC profiles of ganglioside fractions were essentially
similar among the six mouse groups (data not shown).
TABLE 1. Negative-ion LSIMS analysis of major lipids
Compound m/z Ion Structure
Neutral glycolipids
GlcCer 826 [M-H]2 24h:0/d18:1
828 [M-H]2 24:0/t18:0
844 [M-H]2 24h:0/t18:0
GalCera 826 [M-H]2 24h:0/d18:1





SM4sa 906 [M-H]2 24h:0/d18:1
778 [M-H]2 16:0/d18:1
SM3 1070 [M-H]2 24:0/t18:0
1042 [M-H]2 22:0/t18:0




GM3(NeuAc) 1263 [M-H]2 24:0/d18:1
GM3(NeuGc) 1279 [M-H]2 24:0/d18:1
Phospholipids
PI 885 [M-H]2 18:0/20:4
PS 810 [M-H]2 18:0/20:4
CL 1447 [M-H]2 (18:2)4
SM 799 [M-15]2 24:0/d18:1
The DEAE-Sephadex fractions containing each lipid were pooled
and an aliquot was separated by one- or two-dimensional TLC. Each
band on the plate was analyzed with a triethanolamine matrix after
blotting to polyvinylidene difluoride membranes.
a Not detected in the kidney of Cgt2/2 mice.
TABLE 2. Concentrations of sulfolipids in the kidney
Concentration (nmol SO422/g wet tissue)
SM4s SM3 SB1a HSO3-Chol
Male
1/1 275 22 20 44
1/2 290 27 18 42
2/2 ND 42 65 42
Female
1/1 296 24 21 44
1/2 240 22 20 58
2/2 ND 44 69 58
Abbreviation: ND, not detected.
Each pooled fraction of DEAE-Sephadex containing SM4s 1 SM3,
HSO3-Chol, or SB1a was hydrolyzed in 1 m HCl at 1008C for 3.5 h. After
partition in the Folch system, SO422 in the upper phase was deter-
mined by ion chromatography. The ratios of SM3 to SM4s in the kid-
neys of wild-type and Cgt1/2 mice were determined by TLC-densitome-
try after staining with Azure A. Data are expressed as the means of
duplicate experiments.
Fig. 2. Elution profiles of acidic lipids from the
kidney of female wild-type (top) and Cgt2/2 (bot-
tom) mice. Acidic lipids were eluted from a DEAE-
Sephadex A-25 column by a concave gradient of
ammonium acetate, and samples from every two
tubes were applied on the plate. The plate was de-
veloped in chloroform –methanol–water 60:40:9
(v/v/v) containing 0.2% CaCl2 and stained with
the orcinol reagent.
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Major gangliosides identified by LSIMS were GM3(NeuAc)
and GM3(NeuGc) (Table 1), which comprised 40% (10.2
nmol/g) and 25% (6.2 nmol/g), respectively, of the total
ganglioside sialic acids (26 nmol/g) in the kidney of the
male wild-type mice. HPLC analyses of NeuAc and NeuGc
in mono-, di-, and trisialosyl fractions from DEAE-Sepha-
dex showed no significant differences in their concentra-
tions among the six groups (data not shown). These find-
ing on kidney gangliosides was consistent with the normal
brain ganglioside composition in Cgt2/2 mice (27).
The composition of major acidic phospholipids includ-
ing phosphatidylserine (PS), phosphatidylinositol (PI),
and cardiolipin (CL), as well as sphingomyelin (SM), in
Cgt2/2 kidney was compared with those in wild-type and
Cgt1/2 littermates. No changes in the composition and con-
centration of these phospholipids could be observed
among the six groups (data not shown). In the kidney of
male wild-type mice, concentrations (micromoles of PO4
per g wet tissue) of PS, PI, CL, and SM were 3.8, 2.5, 6.3,
and 3.0, respectively. Major molecular species were identi-
fied as PS(18:0/20:4), PI(18:0/20:4), CL(18:2)4, and
SM(24:0/d18:1) by negative-ion LSIMS (Table 1). Unlike
the brain of Cgt2/2 mice (4), SM containing 2-hydroxy
fatty acids (HFA-SM) could not be detected in the kidney.
DISCUSSION
Transcripts of the Cgt gene were clearly detected in the
normal kidney (28) and testis (29, 30) in addition to the
cerebrum and cerebellum (data not shown), suggesting
that the loss of this enzyme activity may affect the function
of these tissues and consequently contribute to the pheno-
type of the mutants. With this hypothesis in mind, we ex-
amined changes in the lipid composition of the kidney of
CGT-deficient mice.
HexCer from the kidney of wild-type mice consisted of
four species, of which one was identified as GalCer and
the others as GlcCer. It has been reported that both
GlcCer containing 2-hydroxy fatty acids (HFA-GlcCer)
and HFA-SM were expressed in compensation for GalCer
in the brain of CGT-deficient mice (4). In the kidney of
Cgt2/2 mice, GalCer was absent, as expected. In contrast,
two bands of GlcCer containing t18:0 sphingosine, which
are the major molecular species of HexCer in rat kidney
(11), were substantially increased. No differences were
seen in the level and species of SM; HFA-SM could be de-
tected neither in Cgt2/2 mice nor in wild-type and Cgt1/2
littermates. It has been expected that in the absence of
CGT activity, the lack of GalCer and Ga2Cer could stimu-
late the synthesis of GlcCer as well as LacCer in compensa-
tion. Unexpectedly, LacCer could hardly be detected in
the kidney of six groups, suggesting its prompt conversion
to SM3 and GM3.
Staining with monoclonal antibodies showed that sul-
foglycolipids are distributed on the lumenal (apical) cell
surface of renal tubules (7, 31). The enrichment of sulfo-
lipids in osmoregulatory organs including kidney and in-
testine has suggested that sulfolipids play important roles
as the ion barrier at the cell membrane (8). The present
study confirms our hypothesis that the sum of sulfogly-
colipids is more concentrated in the kidney of smaller ani-
mals (8, 32), suggesting that the glycolipid-bound sulfate
may participate more actively in the kidney of smaller ani-
mals such as mice. However, CGT-deficient mice lacking
SM4s showed neither morphological defects in the kidney
nor abnormality in parameters responsible for renal func-
tion. Although these findings do not completely exclude
the possibility that GalCer and/or SM4s may be dispens-
able for normal kidney function, there are other possibili-
ties that are consistent with their functional importance.
First, in place of SM4s, Cgt2/2 mice still express more
polar sulfoglycolipids, that is, SM3 and SB1a, in the kid-
ney. Moreover, both sulfoglycolipids are expressed at
higher levels in Cgt2/2 mice than in wild-type and Cgt1/2
littermates, indicating that the biosynthetic pathway of
SB1a from GlcCer via LacCer and SM3 is stimulated in the
kidney of Cgt2/2 mice (Fig. 3), similar to the changes in
SM4s and SM3 in MDCK cells under osmotic stresses (33).
In contrast, no increase in the levels of HSO3-Chol as well
as gangliosides was observed. Because of the formidable
compensatory capacity of the kidney cells to the osmotic
environments ranging between 0 and 1200 mOsm, it is
possible that the increment of SB1a and SM3 can, at least
partially, compensate for the lack of SM4s and allow keep-
ing the normal function of the kidney in Cgt2/2 mice.
Second, it could not be ruled out that acidic phospho-
lipids may partly compensate for the SM4s deficiency.
Third, subtle abnormalities undetectable by routine ex-
aminations under normal environment, might be present
in the kidney of CGT-deficient mice. Experimental manip-
ulations, such as osmotic stress by dehydration, may un-
cover such a borderline functional state of the SM4s-defi-
cient renal tubules.
Brigande, Platt, and Seyfried (34) reported enhanced
synthesis of GalCer-related lipids SM4s and GM4 in the
mouse embryo treated with an inhibitor of ceramide glu-
Fig. 3. Proposed pathway of sulfoglycolipids biosynthesis. In
Cgt2/2 mice, the crossed-out step is blocked. The boxed items rep-
resent the glycolipid, the concentration of which is increased in the
kidney of Cgt2/2 mice.
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cosyltransferase. They suggested that the increases in Gal-
Cer-related lipids may be an adaptive response to prevent
the accumulation of potentially harmful upstream metab-
olites, for example, ceramide. We find these authors’ ar-
gument too teleological. Our view is that the increased
synthesis of the GalCer series of lipids under glucosyl-
transferase-inhibited conditions, as well as that of polar
sulfoglycolipids, in our Cgt knockout mice occurs simply
because more acceptor molecules become available due
to the metabolic block and thus can go to other synthetic
pathways that have a higher Km for the acceptor. Under
both conditions, ceramidase is present in excess and
therefore accumulation of ceramide to a harmful concen-
tration can easily be prevented by degrading it even with-
out increasing the synthetic side reactions. In fact, quanti-
tative estimates indicated clearly that the increase in
GlcCer in the kidney of Cgt2/2 mice is minor and most
of the excess ceramide is being degraded by ceramidase.
The CGT-deficient mouse should allow further analy-
sis of the specific role of GalCer and its derivatives in the
kidney. Because the CGT-deficient mouse generates nei-
ther SM4s nor its precursor, GalCer, precise dissection
of the effect of the precursor and its sulfated end prod-
uct is difficult as yet. GalCer sulfotransferase has been
cloned (35, 36) and we can soon expect a mutant mouse
lacking the capacity to generate sulfated glycolipids.
Comparison of the CGT knockout mouse with the ex-
pected sulfotransferase knockout mouse could answer
the vital question concerning whether both GalCer and
SM4s or only SM4s is important for function. The data
presented in this article should provide the basis for
such a comparison.
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